According to the company, the Curos Port Protector is designed to reduce patient exposure to the risks of hospital acquired bloodstream infections and help maintain hospital infection control protocols.
Bob Rogers, CEO of Ivera Medical, said: “The Curos Port Protector market approval is a significant milestone toward the success of our company. It confirms our commitment to assist healthcare providers in their efforts to reduce bloodstream infections caused by touch or airborne contamination of needleless intravenous ports.”